Drug firm Lupin said on Tuesday it had received a warning letter from the U.S. health regulator for its manufacturing facilities in Goa and Pithampur, Indore.
Lupin said it had responded to all the observations.
“The company has received a warning letter issued by the United States Food and Drug Administration (USFDA) on November 6, 2017, for our formulation manufacturing facilities at Goa and Indore (Pithampur Unit II),” the company said in a filing to BSE.
The drug company, however, did not share the concerns raised by the U.S. health regulator in its warning letter.